This newfound understanding not only deepens our comprehension of S100A2’s role in ccRCC pathogenesis but also opens avenues for potential therapeutic strategies targeting S100A2-related dysregulation in ccRCC. This evidence concerns the gene S100A2 and nonpapillary renal cell carcinoma.